Tacton Launches Connect to Anything, Powered by Workato, Simplifying Integration for Manufacturers
21.1.2025 15:06:00 CET | Business Wire | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and leading SaaS platform simplifying sales and configuration processes for manufacturers of complex products, today announced the launch of its Connect to Anything integration capability, powered by Workato, the leading enterprise orchestration platform. This innovative solution transforms how manufacturers integrate Tacton CPQ into their digital ecosystems, enabling seamless connections to over 600 enterprise applications, including CRM, ERP, PLM, PIM, and analytics tools.
Manufacturers often face costly inefficiencies from data silos and integration roadblocks as IT teams struggle to keep pace with complex connections. The stakes are high: poor data quality costs organizations an average of $12.9 million annually, according to Gartner’s® 2020 Magic Quadrant™ for Data Quality Solutions. Connect to Anything solves this challenge by making it simple to connect data across applications without heavy reliance on IT. With pre-built connectors, reusable recipes, and a no-code approach, Tacton empowers manufacturers to eliminate silos, streamline workflows, and accelerate their digital transformation journey.
“As manufacturers embrace digital transformation, seamless integration across systems has become mission-critical,” saidJesper Alfredsson, Chief Product Officer, Tacton. “Connect to Anything simplifies this process by enabling manufacturers to unify their digital ecosystems, reduce IT dependency, and achieve faster, smarter operations that drive tangible business outcomes.”
With Connect to Anything, manufacturers can:
- Simplify Integration: Seamlessly connect Tacton CPQ to essential systems with pre-built connectors and no-code recipes.
- Accelerate ROI: Achieve faster implementation and operational efficiency with reduced dependency on IT.
- Maximize CPQ Value: Unlock greater returns from CPQ investments with integration capabilities available from the start of implementation.
Connect to Anything brings together unmatched innovation through this partnership. Tacton has been recognized as a Leader in the Gartner® Magic Quadrant™ for CPQ Applications, while Workato is a Leader in the Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS). Together, these industry leaders deliver a powerful solution that helps manufacturers simplify integrations, optimize workflows, and scale operations seamlessly.
“We are thrilled to partner with Tacton, providing manufacturers with seamless integration capabilities that accelerate their journey towards smart factories,” said Nam Le, General Manager of Workato’s Embed Business. “This collaboration exemplifies how leaders in their respective industries can drive powerful outcomes for manufacturers. By embedding Workato’s no-code platform into Tacton CPQ, manufacturers gain unmatched flexibility and efficiency in connecting and optimizing their digital ecosystems. Together, we’re empowering manufacturers to build connected, agile operations that deliver real business value.”
Connect to Anything is available now for manufacturers looking to simplify and accelerate their digital transformation. To learn more about our integration capabilities, visit our website.
About Tacton
Tacton is a leading SaaS company redefining how manufacturers of complex products engage with their buyers. Its cutting-edge buyer engagement platform empowers manufacturers to streamline the buyer journey, deliver personalized, customer-centric experiences, and bring complex products to market faster and more efficiently.
Recognized as a Leader in Gartner’s® Magic Quadrant™ for CPQ Applications, Tacton partners with manufacturers to drive smart factory initiatives and align operations with customer needs. With over 25 years of experience and trusted by more than 100 global leaders like ABB, Daimler, MAN, Scania, Siemens, Xylem, and Yaskawa, Tacton is co-headquartered in Chicago and Stockholm, with regional offices in Karlsruhe, Warsaw, and Tokyo. Learn more at www.tacton.com.
About Workato
Workato transforms technology complexity into business opportunity. As the leader in enterprise orchestration, Workato helps businesses globally streamline operations by connecting data, processes, applications, and experiences. Its AI-powered platform enables teams to navigate complex workflows in real time, driving efficiency and agility. Trusted by a community of 400,000 global users, Workato empowers organizations of every size to unlock new value and lead in today’s fast-changing world. Learn how Workato helps businesses of all sizes achieve more at www.workato.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116707013/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom